Targeting dendritic cells to drive PDAC immunotherapy response

Alyssa G. Weinstein; David G. DeNardo

doi:10.1016/j.tips.2024.10.009

Targeting dendritic cells to drive PDAC immunotherapy response

Alyssa G. Weinstein
, David G. DeNardo

Research output: Contribution to journal › Short survey › peer-review

1 Scopus citations

Abstract

Pancreatic adenocarcinoma (PDAC) has been historically unresponsive to immunotherapy, predominantly due to lower antigen loads and a lack of tumor-infiltrating dendritic cells (DCs) and T cells. A recent study by Mahadevan and colleagues demonstrates that increasing DC infiltration through use of an engineered DC1 vaccine can sensitize PDAC to immunotherapy.

Original language	English
Pages (from-to)	1095-1096
Number of pages	2
Journal	Trends in Pharmacological Sciences
Volume	45
Issue number	12
DOIs	https://doi.org/10.1016/j.tips.2024.10.009
State	Published - Dec 2024

Keywords

adaptive immunity
checkpoint blockade
dendritic cell
pancreatic cancer
pancreatitis

Access to Document

10.1016/j.tips.2024.10.009

Cite this

@article{270c8cafa9774f45a23e46909ee590ad,

title = "Targeting dendritic cells to drive PDAC immunotherapy response",

abstract = "Pancreatic adenocarcinoma (PDAC) has been historically unresponsive to immunotherapy, predominantly due to lower antigen loads and a lack of tumor-infiltrating dendritic cells (DCs) and T cells. A recent study by Mahadevan and colleagues demonstrates that increasing DC infiltration through use of an engineered DC1 vaccine can sensitize PDAC to immunotherapy.",

keywords = "adaptive immunity, checkpoint blockade, dendritic cell, pancreatic cancer, pancreatitis",

author = "Weinstein, \{Alyssa G.\} and DeNardo, \{David G.\}",

note = "Publisher Copyright: {\textcopyright} 2024 Elsevier Ltd",

year = "2024",

month = dec,

doi = "10.1016/j.tips.2024.10.009",

language = "English",

volume = "45",

pages = "1095--1096",

journal = "Trends in Pharmacological Sciences",

issn = "0165-6147",

number = "12",

}

TY - JOUR

T1 - Targeting dendritic cells to drive PDAC immunotherapy response

AU - Weinstein, Alyssa G.

AU - DeNardo, David G.

PY - 2024/12

Y1 - 2024/12

N2 - Pancreatic adenocarcinoma (PDAC) has been historically unresponsive to immunotherapy, predominantly due to lower antigen loads and a lack of tumor-infiltrating dendritic cells (DCs) and T cells. A recent study by Mahadevan and colleagues demonstrates that increasing DC infiltration through use of an engineered DC1 vaccine can sensitize PDAC to immunotherapy.

AB - Pancreatic adenocarcinoma (PDAC) has been historically unresponsive to immunotherapy, predominantly due to lower antigen loads and a lack of tumor-infiltrating dendritic cells (DCs) and T cells. A recent study by Mahadevan and colleagues demonstrates that increasing DC infiltration through use of an engineered DC1 vaccine can sensitize PDAC to immunotherapy.

KW - adaptive immunity

KW - checkpoint blockade

KW - dendritic cell

KW - pancreatic cancer

KW - pancreatitis

UR - https://www.scopus.com/pages/publications/85208238647

U2 - 10.1016/j.tips.2024.10.009

DO - 10.1016/j.tips.2024.10.009

M3 - Short survey

C2 - 39510862

AN - SCOPUS:85208238647

SN - 0165-6147

VL - 45

SP - 1095

EP - 1096

JO - Trends in Pharmacological Sciences

JF - Trends in Pharmacological Sciences

IS - 12

ER -

Targeting dendritic cells to drive PDAC immunotherapy response

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this